CN Patent

CN101939020B — 地加瑞克在制备治疗转移期前列腺癌的药物中的应用

Assigned to Ferring International Center (switzerland) S A · Expires 2012-12-26 · 13y expired

What this patent protects

本发明提供了用于治疗受试者中的转移期前列腺癌的包含地加瑞克的组合物。

USPTO Abstract

本发明提供了用于治疗受试者中的转移期前列腺癌的包含地加瑞克的组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN101939020B
Jurisdiction
CN
Classification
—
Expires
2012-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Ferring International Center (switzerland) S A
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.